中指院:去年百強房企銷售額按年增3.9% 市場份額佔五成
中指院發布《2022中國房地產百強企業研究報告》顯示,2021年,百強企業銷售總額及銷售面積分別為9.08萬億元人民幣(下同)及約5.69億平方米,按年增長3.9%及1.6%。隨著房地產行業進入加速出清及優勝劣汰的階段,百強企業的市場份額下滑0.4個百分點至49.9%。
數據顯示,去年百強企業營業收入及淨利潤均值分別為498.6億元及56.2億元,按年分別增長19.3%及0.4%,增速較上年增加1.6及減少1.5個百分點。
報告指出,受新冠疫情、房地產調控政策持續及各類成本居高不下等因素影響,百強企業淨利潤率均值及淨資產收益率均值較上年分別下降2.2個百分點及1.8個百分點。(ta/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.